Jade Biosciences (NASDAQ:JBIO) Shares Gap Up – Here’s Why

Jade Biosciences, Inc. (NASDAQ:JBIO)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $16.82, but opened at $17.90. Jade Biosciences shares last traded at $18.2050, with a volume of 432,648 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. HC Wainwright increased their price target on Jade Biosciences from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. BTIG Research upped their target price on Jade Biosciences from $39.00 to $74.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Zacks Research raised Jade Biosciences from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. William Blair upgraded Jade Biosciences to a “strong-buy” rating in a research report on Monday, March 9th. Finally, Stifel Nicolaus set a $40.00 price target on Jade Biosciences in a research note on Friday, March 6th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.12.

Jade Biosciences Stock Performance

The stock has a market capitalization of $965.73 million, a P/E ratio of -9.65 and a beta of 1.45. The business has a fifty day simple moving average of $21.02 and a 200-day simple moving average of $16.94.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.05). On average, sell-side analysts anticipate that Jade Biosciences, Inc. will post -2.54 earnings per share for the current year.

Hedge Funds Weigh In On Jade Biosciences

Institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. increased its position in Jade Biosciences by 245.6% in the fourth quarter. RA Capital Management L.P. now owns 3,671,083 shares of the company’s stock worth $56,645,000 after purchasing an additional 2,608,757 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Jade Biosciences in the 1st quarter worth $43,557,000. Baker BROS. Advisors LP purchased a new position in shares of Jade Biosciences in the 4th quarter worth $25,323,000. Remedium Capital Partners LLC bought a new stake in shares of Jade Biosciences in the 4th quarter worth about $24,345,000. Finally, Avidity Partners Management LP increased its holdings in shares of Jade Biosciences by 24.3% in the 4th quarter. Avidity Partners Management LP now owns 1,400,708 shares of the company’s stock worth $21,613,000 after buying an additional 273,522 shares during the last quarter.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.